Using Extracellular miRNA Signatures to Identify Patients with LRRK2-Related Parkinson's Disease.

ABSTRACT

Background: Mutations in the Leucine Rich Repeat Kinase 2 gene are highly relevant in both sporadic and familial cases of Parkinson's disease. Specific therapies are entering clinical trials but patient stratification remains challenging. Dysregulated microRNA expression levels have been proposed as biomarker candidates in sporadic Parkinson's disease. Objective: In this proof-of concept study we evaluate the potential of extracellular miRNA signatures to identify LRRK2-driven molecular patterns in Parkinson's disease. Methods: We measured expression levels of 91 miRNAs via RT-qPCR in ten individuals with sporadic Parkinson's disease, ten LRRK2 mutation carriers and eleven healthy controls using both plasma and cerebrospinal fluid. We compared miRNA signatures using heatmaps and t-tests. Next, we applied group sorting algorithms and tested sensitivity and specificity of their group predictions. Results: miR-29c-3p was differentially expressed between LRRK2 mutation carriers and sporadic cases, with miR-425-5p trending towards significance. Individuals clustered in principal component analysis along mutation status. Group affiliation was predicted with high accuracy in the prediction models (sensitivity up to 89%, specificity up to 70%). miRs-128-3p, 29c-3p, 223-3p, and 424-5p were identified as promising discriminators among all analyses. Conclusions: LRRK2 mutation status impacts the extracellular miRNA signature measured in plasma and separates mutation carriers from sporadic Parkinson's disease patients. Monitoring LRRK2 miRNA signatures could be an interesting approach to test drug efficacy of LRRK2-targeting therapies. In light of small sample size, the suggested approach needs to be validated in larger cohorts.

We know that alterations in a gene called Leucine Rich Repeat Kinase 2 are important in both inherited and non-inherited cases of Parkinson's disease. We also know that treatments for Parkinson's disease specifically targeting LRRK2 are currently being developed. Challenges for developing such a treatment, however, are how to accurately identify patients who could benefit from these therapies and to observe whether the treatment interacts with its target on a molecular level. In this study, we tested whether individuals with an alteration in the LRRK2 gene display a distinct pattern of small RNA molecules, called microRNAs. We measured the amount of 91 microRNAs present in blood of individuals with an alteration in the LRRK2 gene and compared their pattern to patients with a non-inherited form of Parkinson's disease and healthy controls.We found that the amount of a specific microRNA called miR-29c-3p was different between individuals with or without an alteration of the LRRK2 gene. Additionally, we developed models that could predict whether someone had a LRRK2 mutation based on the microRNA pattern in the plasma. Of course, we have easier methods to find these gene alterations, but our findings suggest that changes of LRRK2 result in a shift of microRNA patterns in the blood. This could help us to observe the effects of a LRRK2 specific treatment which tries to revert these changes. As we know that LRRK2 also plays a role in some patients with a non-inherited form of Parkinson's disease, this microRNA pattern could maybe even help us to identify these individuals. It is important to note that our study involved a small number of individuals, so that further research with larger groups is needed to confirm our findings.